Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Jan;29(1):122-8.
doi: 10.1038/eye.2014.251. Epub 2014 Oct 24.

Rituximab for the treatment of IgG4-related orbital disease: experience from five cases

A Wu  1 , N H Andrew  1 , A Tsirbas  2 , P Tan  3 , A Gajdatsy  3 , D Selva  1
Affiliations
Case Reports

Rituximab for the treatment of IgG4-related orbital disease: experience from five cases

A Wu et al. Eye (Lond). 2015 Jan.

Abstract

Purpose: To review the clinical efficacy and safety of rituximab for treatment of IgG4-related orbital disease (IgG4-ROD).

Design: Retrospective multicentre interventional case series.

Methods: Chart review for five cases of biopsy-confirmed IgG4-ROD (IgG4+>10/HPF, ratio of IgG4+/IgG+>40%) treated with rituximab. Information retrieved included the dosing schedule, adverse events and the magnitude, temporality, and duration of the clinical response.

Results: All cases of IgG4-ROD were either steroid dependent or steroid resistant. Rituximab doses for induction therapy included two doses of 1000 mg at 2-weekly intervals, and four doses at 375 mg/m(2) at weekly intervals. Two months after starting rituximab, three cases achieved complete clinical resolution and two cases achieved partial clinical resolution. Complete radiological resolution occurred in one case, and partial radiological resolution in three cases. Three cases received rituximab maintenance therapy and one case was commenced on mycophenolate. No relapse occurred during a mean follow-up of 33 months (range: 7-65 months). One disease relapse occurred when the dosing interval of rituximab maintenance therapy was extended to 6-monthly intervals; remission was swiftly achieved with rituximab reinduction therapy. The only adverse effects reported were one episode of fatigue lasting 1 week and two episodes of orbital discomfort.

Conclusion: Rituximab may be an effective treatment option for IgG4-ROD that is steroid dependent or steroid intolerant. Rituximab therapy resulted in swift clinical and radiological improvement, many months free of relapse, and few side effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Left superior orbital mass (white arrow) in Case 1 significantly reduced in size following rituximab treatment. No abnormality detected at 2-year follow-up. Axial computed tomography pre-treatment (top); computed tomography at 2-month follow-up (middle); and computed tomography at 2-year follow-up (bottom).
See this image and copyright information in PMC

References

    1. Andrew N, Kearney D, Selva D. IgG4-related orbital disease: a meta-analysis and review. Acta Ophthalmol. 2013;91 (8:694–700. - PubMed
    1. Hamano H, Arakura N, Muraki T, Ozaki Y, Kiyosawa K, Kawa S. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol. 2006;41 (12:1197–1205. - PubMed
    1. Takuma K, Kamisawa T, Anjiki H, Egawa N, Igarashi Y. Metachronous extrapancreatic lesions in autoimmune pancreatitis. Intern Med. 2010;49 (6:529–533. - PubMed
    1. Ebbo M, Daniel L, Pavic M, Seve P, Hamidou M, Andres E, et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore) 2012;91 (1:49–56. - PubMed
    1. Deschamps R, Deschamps L, Depaz R, Coffin-Pichonnet S, Belange G, Jacomet PV, et al. High prevalence of IgG4-related lymphoplasmacytic infiltrative disorder in 25 patients with orbital inflammation: a retrospective case series. British J Ophthalmol. 2013;97 (8:999–1004. - PubMed

MeSH terms

LinkOut - more resources